[Drug treatment for hypertrophic cardiomyopathy].
Drug treatment of hypertrophic cardiomyopathy is the first-line treatment, at the onset of clinical signs and symptoms. Beta-blockers are proposed for symptomatic patients with no gradient or with a gradient that appears only on exertion. Verapamil is the standard second-line drug,when the beta-blockers are insufficient or ineffective but must be avoided when there is blockage at rest with severe symptoms. Disopyramide is indicated for patients with obstruction who do not respond to beta blockers and/or verapamil. Treatment with anticoagulants is widely prescribed because this disease is highly emboligenic.
Gibelin
Pierre
P
Service de cardiologie, Hôpital Pasteur, CHU Nice, Nice Cedex 1, France. gibelin.p@chu-nice.fr
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000209:etiology; D002312:Cardiomyopathy, Hypertrophic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D002637:Chest Pain / Q000209:etiology; D016757:Death, Sudden, Cardiac / Q000209:etiology; D004206:Disopyramide / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D016903:Drug Monitoring; D004417:Dyspnea / Q000209:etiology; D004617:Embolism / Q000209:etiology / Q000517:prevention & control; D004696:Endocarditis / Q000209:etiology; D054143:Heart Failure, Systolic / Q000209:etiology; D006801:Humans; D017202:Myocardial Ischemia / Q000209:etiology; D018579:Patient Selection; D014665:Vasodilator Agents / Q000627:therapeutic use; D014700:Verapamil / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D004232:Diuretics; D014665:Vasodilator Agents; D014700:Verapamil; D004206:Disopyramide